Rubella Diagnostic Testing Market Size, Share & Trends Analysis Report By Testing Technique (Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), Fluorescent Immunoassay (FIA)), By Application (Hospitals, Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Market Overview

The global rubella diagnostic testing market size was valued at USD 5.28 billion in 2025 and is projected to grow from USD 5.54 billion in 2026 to USD 8.12 billion by 2034, registering a CAGR of 4.9% during the forecast period from 2026 to 2034. North America dominated the rubella diagnostic testing market with a market share of 36.4% in 2025.

The increasing number of Rubella diagnostic tests, combined with government attempts to decrease infection rates and advancements in point-of-care diagnosis, is expected to drive market expansion throughout the projection period.

Rubella diagnostic testing identifies and detects the presence of the Rubella virus or antibodies produced in response to Rubella infection in clinical specimens collected from people suspected of having Rubella. Rubella, commonly known as German measles, is a contagious viral infection with a striking red rash. Rubella diagnostic testing is crucial for verifying illness, managing patients, and preventing spread.

In addition, government initiatives to combat the rubella virus, rising rubella occurrences, and developing enhanced point-of-care diagnostic technologies are all driving expansion in the market under consideration. Individuals are becoming more aware of the importance of speedy rubella diagnostics due to increased government initiatives pushing the market. Additionally, the development of point-of-care diagnostics for rubella diagnosis is propelling the growth of the studied industry. Thus, the market is likely to rise significantly throughout the forecast period due to government measures to combat the rubella virus, rising rubella occurrences, and the development of new point-of-care diagnostic technologies. However, a lack of awareness in developing countries may delay expansion throughout the research.

Segmental Analysis

The global rubella diagnostic testing market is segmented based on testing technique, application, and region.

The market is further segmented by testing technique into Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), and Fluorescent Immunoassay (FIA).

The enzyme immunoassay category now has most of the Rubella diagnostic testing market share. Enzyme immunoassay (EIA) reagents and devices are used to detect the presence or concentration of an antigen, which is then applied to epidemiological disease detection. It includes several enzymes, such as alkaline phosphatases and glucose oxidase. The rubella virus can live in the bloodstream for years before being destroyed by antibodies produced by the immune system. IgM testing is the most common method for commercial enzyme immunoassay (EIA) kits. Because all matched specimens tested from patients with acute rubella infection showed a considerable increase in antibody levels, the enzyme immunoassay (EIA) can also be used to detect acute infections. The increasing prevalence of infectious disorders such as Rubella is the primary reason for the rise of the enzyme immunoassay (EIA) segment.

Furthermore, the test's feasibility and accuracy also contribute to the segment's expansion. For example, an article published by mSphere in July 2021 stated that measles and Rubella are two of the most globally important vaccine-preventable diseases (VPD) and that measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities. That enzyme immunoassay is the most convenient method and approach for detecting the rubella virus.

Latex agglutination assays detect Rubella-specific antibodies by generating visible clumping (agglutination) of latex particles coated with Rubella antigens when combined with the patient's serum or plasma. While quick and easy, these tests may have lesser sensitivity than other procedures and are frequently employed as screening tests rather than confirmatory diagnoses.

Request Customizationto receive a tailored report.

By application, the segment can be further bifurcated into Hospitals and laboratories.

The hospital segment dominates the application segment of the global rubella diagnostic testing market, with a 40% market share in 2023, and is expected to develop rapidly during the forecast period. Hospitals play an important role in Rubella diagnostic tests, especially in the clinical management of patients who come with Rubella-like symptoms or consequences. Rubella diagnostic tests are routinely conducted in various hospital departments, including emergency rooms, pediatric wards, obstetrics and gynecology departments, and infectious disease units. Patients suspected of having Rubella infection may receive diagnostic testing as part of their clinical evaluation, with the results used to guide treatment options, infection control measures, and patient counseling.

Additionally, the segment's rise is linked to increased hospitals and the introduction of technology that provides quick results. Furthermore, government financing and legislation drive significant growth in the healthcare industry. The increasing prevalence of infectious diseases is expected to drive market expansion shortly. As a result, these factors are projected to drive the expansion of rubella diagnostics over the forecast period.

Rubella diagnostic testing relies heavily on diagnostic laboratories, including clinical and reference labs. These laboratories have the requisite infrastructure, apparatus, and competence to perform various Rubella diagnostic tests, including serological and molecular assays. Rubella testing services in the laboratory may be provided as part of routine clinical testing menus, specific infectious disease testing panels, or prenatal screening programs. Laboratory professionals conduct Rubella testing, analyze the results, and report them to healthcare providers for patient management and public health surveillance.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The global rubella diagnostic testing market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global rubella diagnostic testing market shareholder and is estimated to grow at a CAGR of 4.6% over the forecast period. The North American region is predicted to develop significantly over the forecast period due to essential market participants, significant government programs, and technical advancements related to this condition's appropriate and prompt diagnosis. Furthermore, considerable government measures are causing a decrease in rubella cases across the country. For example, in January 2022, the Government of Canada reported no new cases of measles or Rubella in week 52 of 2021, and there are no active cases of measles or Rubella in Canada today. Canada recorded one case of Rubella in 2023, with the last case reported in September 2023. In 2024, 48 measles cases and one congenital Rubella syndrome/infection were documented. Thus, the government's initiatives to eradicate Rubella through appropriate diagnosis support market expansion.

Similarly, the Centers for Disease Control and Prevention (CDC) announced in January 2021 that Rubella is no longer endemic in the United States. According to the CDC, implementing a high-quality surveillance system is essential for eliminating Rubella in the North American region. The regional administration has established routine immunization for children, which, when supplemented with effective diagnostic campaigns in countries with high case and death rates, is a critical public health strategy for reducing worldwide measles fatalities.

Furthermore, introducing new technologies hastened the region's investigated industry's expansion. For example, an article published in the Journal of Virology Methods in May 2022 stated that the COVID-19 pandemic has disrupted rubella vaccination services all over the world, resulting in an increased immunity gap, and RV genotype surveillance is a critical component of monitoring progress toward rubella elimination and eradication goals. This RuV multiplex assay will provide sensitive and accurate test findings quickly. Such research and the development of new diagnostics are fueling the region's market expansion.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific is anticipated to exhibit a CAGR of 5.3% over the forecast period. The growing population and improved healthcare facilities with simple access are expected to drive market expansion. Furthermore, increased demand for lower healthcare costs will drive market expansion. Asia Pacific's dominant countries include India, China, and Japan, owing to significant market participants in the region. Furthermore, Asia Pacific has seen the most robust growth in the rubella diagnostics testing market, which is expected to continue at this rate. Moreover, a lack of awareness in a developing country and government measures will likely keep the market growing.

Europe holds a significant market share. Vaccination regulations, healthcare infrastructure, and disease epidemiology all impact Europe's rubella diagnostic testing industry. Many European countries have long-standing Rubella vaccine regimens as part of their national immunization schedules. For example, the European Centre for Disease Prevention and Control (ECDC) recommends Rubella vaccination as part of a standard pediatric immunization schedule, commonly given as a combined measles, mumps, and Rubella (MMR) vaccine. Countries such as Germany, France, and the United Kingdom have excellent vaccine coverage rates, which help to limit Rubella transmission and avoid congenital Rubella syndrome (CRS).

List of Key and Emerging Players in Rubella Diagnostic Testing Market